TL;DR
Austin's medical device base skews toward software-driven and connected devices, which reshapes how products liability, cyber, and technology E&O fit together. Coverage should be built around device class, IDE clinical trial exposure, and the additional-insured obligations embedded in hospital and GPO supplier contracts. We place these programs through A-rated specialty markets using Texas's deep surplus-lines availability.
Austin medical device
Austin has become one of the fastest-growing technology and health-technology ecosystems in the country, and its medical device base is expanding alongside the Dell Medical School at the University of Texas at Austin and a deep bench of local software talent. That software depth pulls the regional device profile toward software-driven and connected products, where the underlying technology is often as important to the liability picture as the physical hardware. Insurance for these companies has to account for both the device itself and the code that runs it.
A device manufacturer or developer in Austin typically needs a program that reads across products liability, clinical trial exposure, cyber, and technology errors and omissions, rather than a single off-the-shelf policy. Because Texas is a business-dense state with strong surplus-lines availability, these risks can generally be placed efficiently through A-rated specialty markets that understand the device lifecycle. The goal is a tower that scales with the regulatory class of the product and the contracts the company is asked to sign.
Last updated 2026-07-14
Cluster shape
Austin's life-sciences growth is closely tied to its software identity, which means many local device companies build connected hardware, remote-monitoring platforms, or software that itself functions as a medical device. This concentration of software-driven products distinguishes Austin from metros where the device base is dominated by traditional implantables or capital equipment. The result is a risk profile where digital exposure and product exposure are frequently the same exposure.
The presence of the Dell Medical School and a broad academic and clinical research environment supports early-stage device development, investigational studies, and the kind of iterative, data-heavy product design that connected devices require. Companies at this stage often move quickly from prototype to clinical evaluation to commercial supply agreements, and each transition changes the coverage they need. An insurance program that fit a pre-revenue developer rarely fits the same company once it is shipping product into hospitals.
Because the local ecosystem blends engineers, clinicians, and software teams, many Austin device companies underestimate how their commercial contracts allocate liability. Hospital systems and group purchasing organizations impose specific insurance requirements, and Austin's software-oriented founders are not always prepared for products-liability contract language. Getting the coverage architecture right early prevents a scramble when the first large purchase agreement arrives.
Coverage architecture
Products liability is the anchor coverage, and it should be sized to the device class. A Class I product carries a very different loss profile than a Class II or Class III device, and the products tower should reflect that gradient, with market-typical program limits often running in the $5M-$25M range for commercial-stage manufacturers depending on class, distribution, and body-contact profile. Companies running investigational studies also need IDE clinical trial coverage that responds to subject injury and protocol-related exposures before the product reaches the market.
Contracts drive much of the coverage design. Hospital purchase contracts and GPO supplier agreements, including those administered through organizations such as Vizient, Premier, and HealthTrust, routinely require additional-insured status covering both products AND completed operations, primary and non-contributory wording, and specified minimum limits. A common and costly gap is a blanket additional-insured endorsement that silently excludes products and completed operations, which can leave a supplier out of compliance with the very contract it just signed. Product recall should also be addressed as a separate first-party trigger, since a recall can generate direct costs well before any liability claim is filed.
Given Austin's tilt toward software-driven and connected devices, cyber and technology errors and omissions frequently become a primary vehicle for product-liability-style exposure rather than an ancillary line. For software as a medical device, a defect in the algorithm or a data-integrity failure can produce patient harm that a traditional products policy may not fully answer, so the cyber and tech E&O placement has to be coordinated with the products tower. We structure these lines so the connected-device exposure is covered on purpose, not by accident.
Regulatory + market context
Texas is a large, business-dense state with well-developed surplus-lines infrastructure, which gives Austin device companies broad access to A-rated specialty markets that write products liability, clinical trial, and technology risks. That availability matters because device and health-tech exposures often fall outside standard-market appetite and are better served by carriers that underwrite the device lifecycle directly.
Device classification and clinical study status remain the central drivers of both regulatory obligation and insurability, so a company's FDA class and its IDE or commercial posture should inform how the program is built and reviewed. As products move from investigational use to commercial distribution and into GPO and hospital supply channels, the insurance program should be re-underwritten to keep limits, additional-insured wording, and recall coverage aligned with current contracts.
Frequently asked
Austin's device base skews toward software-driven and connected products, reflecting the city's deep software talent and health-tech growth. That means cyber and technology errors and omissions often sit alongside, and sometimes ahead of, traditional products liability in the coverage design. A program built for a purely mechanical device will usually leave software and data exposures underinsured for an Austin company.
The products tower should scale with the FDA classification of the device. Class I products generally carry lower body-contact and harm profiles, while Class II and especially Class III devices warrant higher limits, with commercial-stage programs commonly falling in the $5M-$25M range depending on class, distribution footprint, and contract requirements. Class is the starting point, and distribution and hospital-contract terms then refine the number.
Hospital purchase contracts and GPO supplier agreements, including those tied to organizations such as Vizient, Premier, and HealthTrust, typically require additional-insured status covering products AND completed operations, primary and non-contributory language, and specified minimum limits. A frequent gap is a blanket additional-insured endorsement that excludes products and completed operations, which quietly puts the supplier out of compliance. The certificate and endorsement wording should be matched to the contract before it is signed.
For software-driven and connected devices, including software as a medical device, cyber and technology errors and omissions frequently function as a primary product-liability vehicle. A defect in the algorithm or a data-integrity failure can cause patient harm that a traditional products policy may not fully address, so those lines have to be coordinated rather than bought in isolation. We structure the program so the connected-device and software exposure is covered deliberately across the products and technology towers.
Free coverage review
Programs placed through A-rated specialty markets. Send your contract, insurance schedule, or current COI - a specialist returns a clause-by-clause read by end of business day.